focus -WSS

focus

author：knowledge 2025-10-01 18:35:15 - browse：7

Blood corpuscles in clot — Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success. David Gregory & Debbie Marshall/Wellcome Images

Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success.

LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries. The tool is meant only for patients with a severe form of peripheral artery disease, and who have already tried more conservative options.

Dan Rose, CEO of LimFlow, previously told STAT that his mission is to fight the amputation epidemic in the United States, which disproportionately impacts Black patients. Experts cautioned to STAT that expanding screenings to catch the disease early is still the most important measure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Medicare isn't yet testing food as medicine

focus

WSS

Childhood vaccination ad campaign launches in the U.K.

Colorectal cancer study finds potential in overlooked immune cell

A Q&A with the global head of Boehringer Ingelheim's innovation unit

3 questions for the future of Biden's cancer moonshot

STAT Madness 2024: Meet the contenders

'Vaccine

hotspot

focus

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Colorectal cancer study finds potential in overlooked immune cell

DIEP, the 'gold standard' of breast reconstruction, is under threat

A virus, fished out of a lake, may have saved a man’s life

New air purifier tech could be key to improving indoor air quality

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

After affirmative action ruling, medical educators look to 'holistic review'

CDC advisory group OKs chikungunya vaccine

The high cost of giving birth even with insurance

CDC advisory group OKs chikungunya vaccine

entertainment

Senate panel eyes new effort on drug shortages

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

A Q&A with the global head of Boehringer Ingelheim's innovation unit

A virus, fished out of a lake, may have saved a man’s life

Medicare Advantage isn’t working — for anyone

Analysis of telehealth claims data suggest service duplication

focus

knowledge

focus

focus